<DOC>
	<DOCNO>NCT00650858</DOCNO>
	<brief_summary>The specific objective trial determine low dose dose frequency possible best pharmacokinetic safety profile 's ability remove blood clot ventricular system .</brief_summary>
	<brief_title>Clinical Trial Treatment Intraventricular Hemorrhage</brief_title>
	<detailed_description>The purpose trial determine efficacy pharmacokinetics intraventricular injection multiple low dos rt-PA. Sixteen subject already randomize receive intraventricular injection 0.3 mg 1.0 mg rt-PA every 12 hour 8 dos . Results stage ( n=16 ) analyze effective dose 1.0 mg chosen use second stage ( n=36 ) determine optimal frequency dose . We propose test intervention facilitates rapid clot resolution , complete recovery function decrease mortality condition .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Plasminogen</mesh_term>
	<mesh_term>Fibrinolytic Agents</mesh_term>
	<mesh_term>Tissue Plasminogen Activator</mesh_term>
	<criteria>1 . Age 1875 2 . IVC place standard care use less equal 2 complete pass . 3 . Spontaneous ICH le equal 30 cc . 4 . Able receive first dose within 48 hour CT scan diagnosing IVH ( provide time symptom onset diagnostic CT exceed 12 hour ) . 5 . Clot size measure CT scan do 6 hour IVC placement must equal presentation clot size plus minus 5 cc ( determined AxBxC ) /2 method ) . 6 . ON stability CT scan either 3rd 4th ventricle occlude blood ( evidence CSF flow CT ) . 7 . SBP &lt; 200 mmHg sustain 6 hour . 8 . Historical Rankin 0 1 . 1 . Suspected untreated aneurysm AVM ( unless rule angiogram MRA/MRI ) . 2 . Clotting disorder . 3 . Patients platelet count &lt; 100,000 , INR &gt; 1.7 , PT &gt; 15 , elevate APTT . 4 . Pregnancy ( positive pregnancy test ) . 5 . Infratentorial hemorrhage ( i.e. , parenchymal/posterior fossa hematoma ; cerebellar hematoma exclude ) . 6 . SAH ( An angiogram obtain diagnostic CT scan demonstrates subarachnoid hemorrhage hematoma location appearance strongly associate hypertension . If angiogram demonstrate bleed source account hemorrhage , patient eligible study ) . 7 . ICH enlargement 6hour stabilization period ( 6 hour IVC placement ) . 8 . Internal bleeding , involve retroperitoneal site , gastrointestinal , genitourinary , respiratory tract . 9 . Superficial surface bleeding , observe mainly vascular puncture access site ( e.g. , venous cutdowns , arterial puncture ) site recent surgical intervention . 10 . Known risk embolization , include history leave heart thrombus , mitral stenosis atrial fibrillation , acute pericarditis , subacute bacterial endocarditis . 11 . Prior enrollment study . 12 . Any condition investigator believe would pose significant hazard subject investigational therapy initiate . 13 . Participation another simultaneous medical investigation trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>Intraventricular hemorrhage ( IVH )</keyword>
	<keyword>rt-PA</keyword>
</DOC>